NEPH (.61) is in a similar situation as OCLS was whose stock has gone $1.09 (5/22) to $4.40 (6/4)on FDA 510K approval and expanded use. The difference is NEPH has the better opportunity to obtain 2 FDA approvals and not just 1 with expanded use! This could send the stock well over $2 in my opinion if approval occurs. If it does not get approved for 1 product does not mean all is over as a second approval is on the table as well. I could be wrong but at .60 NEPH seems undervalued given the potential from my research & IMO. This post is my DD, my research, and my opinion only.
Not a huge follower of Adam Feuerstein but he is considered in the know on biotech topics. Wrong w/HEB though! OCLS gets approved via a 510k which is not as stringent as a PMA for a drug even though the patient applies topically on skin with limited data. Feuerstein states...
"Oculus is trying to develop Microcyn as a drug to treat diabetic foot ulcers. The company completed a phase II study in early 2008 (the results weren't remarkable) and since then, the company's been talking about a phase III study but can't seem to get out of the planning stages.
I've never understood why Oculus believed that a product that is essentially a medical version of Clorox Anywhere would have any luck becoming an FDA-approved drug.
But if that chance exists, someone should tell Clorox so it can start advertising as a biopharmaceutical company." Biotech Stock Mailbag: Oculus in Focus http://www.thestreet.com/print/story/10507035.html
News 
Market Data 
Discover 
AI
